PathoVax was founded in late 2014 and is currently managed by myself (Weijie Poh, PhD) and Joshua Wang, PhD. We are both Singaporeans who were awarded fellowships to attend the Pathobiology graduate program at Johns Hopkins University, which is where the RGVax platform was developed.
We also received training in Singapore under esteemed A*STAR investigators Dr Axel Ulrich (Weijie Poh) and Dr Lisa Ng (Joshua Wang). My research background included infectious diseases and cancer, and I have previously managed a biotech startup (Vector BioLabs) in Philadelphia where I oversaw business development, marketing and product expansion.